The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 03, 2018
Filed:
Nov. 08, 2016
Applicant:
Janssen Biotech, Inc., Horsham, PA (US);
Inventors:
Mark Cunningham, Kennett Square, PA (US);
Yiqing Feng, Wayne, PA (US);
Katharine Heeringa, Wayne, PA (US);
Jinquan Luo, Malvern, PA (US);
Robert Rauchenberger, Martinsried, DE;
Mark Rutz, Martinsried, DE;
Lani San Mateo, Devon, PA (US);
Robert Sarisky, Lansdale, PA (US);
Raymond Sweet, Bryn Mawr, PA (US);
Fang Teng, Chesterbrook, PA (US);
Alexey Teplyakov, Phoenixville, PA (US);
Sheng-Jiun Wu, Broomall, PA (US);
Assignee:
Janssen Biotech, Inc., Horsham, PA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07H 21/04 (2006.01); C12N 15/117 (2010.01); C07K 14/705 (2006.01); C12N 5/10 (2006.01); C12N 5/12 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 39/3955 (2013.01); C07H 21/04 (2013.01); C07K 16/28 (2013.01); C12N 15/117 (2013.01); A61K 2039/505 (2013.01); C07K 14/705 (2013.01); C07K 16/2863 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12N 5/10 (2013.01); C12N 5/12 (2013.01); C12N 15/63 (2013.01); C12N 2310/17 (2013.01);
Abstract
Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.